What is Humacyte?
Humacyte, Inc. is at the forefront of developing and manufacturing off-the-shelf, implantable, bioengineered human tissues designed to treat a wide array of diseases and conditions. Leveraging a proprietary technology platform, the company engineers human acellular vessels (HAVs) that are designed to be implanted without eliciting a foreign body response or immune rejection. Humacyte's portfolio targets critical areas within the vascular repair, reconstruction, and replacement market, including vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, pediatric heart surgery, and coronary artery bypass grafting. Furthermore, the company is exploring the application of its HAVs for cellular therapy delivery, such as pancreatic islet cell transplantation for Type 1 diabetes.
How much funding has Humacyte raised?
Humacyte has raised a total of $587.9M across 9 funding rounds:
Series B
$150M
Private Equity
$10M
Unspecified
$14.1M
Other Financing Round
$150M
Debt
$2M
Debt
$50M
Debt
$150M
Series B (2015): $150M supported by Access Industries, Reignwood Group, and Bangkok Bank Public Company Ltd.
Private Equity (2016): $10M featuring California Institute for Regenerative Medicine
Unspecified (2017): $14.1M backed by California Institute of Regenerative Medicine
Other Financing Round (2018): $150M with participation from Fresenius Medical Care
Debt (2020): $2M led by PPP
Debt (2021): $50M supported by Silicon Valley Bank
Debt (2023): $150M featuring Oberland Capital
Key Investors in Humacyte
Oberland Capital
Oberland Capital is a private investment firm focused on funding innovation in the global healthcare industry, managing approximately $3 billion in assets. The firm specializes in flexible investment structures tailored to meet the specific needs of its partners, offering a range of financing solutions including monetization of royalty streams and project-based financing.
Access Industries
Access Industries is a privately-held industrial conglomerate founded in 1986 that makes strategic investments globally. The company focuses on developing regional and global market leaders through long-term value creation.
Reignwood Group
Founded in Thailand in 1984, Reignwood Group is a global Chinese enterprise with headquarters in Hong Kong and offices in Singapore, Thailand, Canada, the USA and UK. Under the Chairmanship of Dr Chanchai Ruayrungruang, the Groups extensive financial resources and global network have created a strategic international platform that not only invests in a wide spectrum of industries, but gives back to society, improves the lives of local Chinese communities and assists in the protection of the environment.
What's next for Humacyte?
With its recent major strategic investment and a history of significant capital raises, Humacyte appears poised for a critical scaling phase. The company's focus on developing implantable, bioengineered human tissues for diverse therapeutic applications suggests a trajectory towards clinical validation and potential commercialization. Future endeavors will likely involve expanding manufacturing capabilities, advancing clinical trials across its portfolio, and navigating regulatory pathways to bring its innovative HAVs to patients in need. The sustained investment indicates strong confidence in Humacyte's technology and its potential to disrupt traditional treatment paradigms in vascular and regenerative medicine.
See full Humacyte company page
